Figures & data
Table 1. Medication methods for six P388 leukemic nude mice groups
Table 2. Real-time PCR primers for Bax, Bcl-2, NF-κB, and GAPDH
Figure 1. P388 xenograft mice models. (A) Nude mice images taken 2 weeks after P388 cell inoculation; (B) nude mice images taken 4 weeks (B) after P388 cell inoculation.
Table 3. Survival time summary for control and experimental groups
Figure 2. White blood cell number of the peripheral blood from each group of P388 leukemic mice. *Significant difference compared with DMSO control group (P < 0.05).
Figure 3. Portions of cells at different cell cycle phases for each group of P388 Xenograft Balb/c nude mice. Left: Cell percentage at G0–G1; right: cell percentage at S–G2M.*Significant difference compared with DMSO control group (P < 0.05).
Figure 4. Que activates Caspase-3 by regulating the expression of BAX, Bacl-2, and NF-κB. (A) Caspase-3 activity comparisons among control group and medication groups. Data were generated from Caspase-3 ELISA; (B) BAX mRNA level in different groups; (C) Bcl-2 mRNA level in different groups; (D) NF-κB mRNA level mRNA level in different groups; (E) BAX, Bacl-2, and NF-κB protein level comparisons among control and medication groups. aComparison with DMSO control group P < 0.05; bcomparison with low-Que group P < 0.05; ccomparison with ADM group, P < 0.05; dcomparison to ADM with low-Que group, P < 0.05.
Figure 5. Ultrastructural changes of cardiomyocyte after ADM medication. Images were taken under TEM (×120 00). (A) DMSO control group; (B) ADM group; and (C) ADM with low-Que group.
Figure 6. Que removes ROS by regulating GSH-Px, SOD, and MDA activities. (A) GSH-Px enzymatic activity comparisons among all groups; (B) SOX enzymatic activity comparisons among all groups; (C) MDA enzymatic activity comparisons among all groups. aComparison with DMSO control group, P < 0.05; bcomparison with ADM group, P < 0.05.
